A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Umoja Biopharma
Massachusetts General Hospital
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Stanford University
Massachusetts General Hospital